Lotte Biologics signed an agreement with Roche Diagnostics to further improve its contract development and manufacturing organization capabilities, the Korean company said Wednesday.
Samsung Biologics inked a $112.5 million contract manufacturing organization (CMO) letter of intent with an unnamed U.S. biopharmaceutical firm, the Korean company said in a regulatory filing on Monday.
Vegzelma, a Celltrion biosimilar of the anticancer drug Avastin, was approved for use by Japanese health regulators, the Korean company said Tuesday.
Of more than a thousand booths at the BIO International Convention (BIO USA), Samsung Biologics' is especially lively with lots of visitors crowding the entrance Monday.
Phase 3 clinical trials of CT-P16, Celltrion's biosimilar of anticancer drug Avastin, produced significant results proving its safety and efficacy, the company announced Wednesday.
Game-changing Covid oral treatments being announced by multinationals are knocking the stuffing out of biopharmaceuticals, both those pursuing vaccine strategies and those looking for oral remedies of their own for the virus.
Korea JoongAng Daily Sitemap
